ATMOCLIF-MR Tablets

Composition
  • Each Uncoated Tablet Contains:
  • Aceclofenac IP
    100 mg
  • Paracetamol IP
    325 mg
  • Chlorzoxazone USP
    250 mg
Packing
  • 20x10
    (Blister)
MRP
  • 65

Overview

Atmoclif-MR is a combination of Aceclofenac, Paracetamol & Chlorzoxazone. Aceclofenac is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti- inflammatory, analgesic, and antipyretic activities.
Paracetamol, also known as Acetaminophen, is commonly used for its analgesic and antipyretic effects.
Chlorzoxazone is a benzoxazolone derivative, Centrally acting Muscle relaxant and mild sedative.

Indications

  • Muscle spasm and pain.

Contraindications

Hypersensitivity,gastrointestinal bleeding, moderate to severe renal impairment, third trimester of pregnancy.
Special Precautions: Caution should be administred in patient with gastrointestinal bleeding, history of peptic ulceration, Cerbrovascular bleeding, ulcerative colitis, Chrons disease, systemic lupus erythromatosus, Prophyria, hemotopiotoic or coagulation disorders, Concomittant use of alcohol, Pregnancy,lactation.

Side Effects

Heratburn, dyspepsia, diarrhea, dizziness, nausea, abdominal pain, flatulence, drowsiness, lightheadedness, headache, excitement, restlesness, irritability, jaundice

Dosage

Oral:
Disclaimer:To be taken only after consulting with the doctor.

Pharmacology

Aceclofenac relieves pain and inflammation through a variety of mechanisms and in addition exerts stimulatory effects on cartilage matrix synthesis. It inhibits various mediators of pain and inflammation Aceclofenac stimulates glycosaminoglycan symthesis in human osteoarthritic cartilage by inhibition of IL 1Beta and suppresses cartllage degeneration by inhibiting IL 1Beta mediated promatrix metalloproteinase production and proteoglycan release Paracetamol is usaeful in providing background and analgesia along other analgesic drugs. The exact mechanism of action of paracetamol is unclear, but its anagesic action is thought to be due to inhibition of prostaglandin synthesis. Its antipyretic property can be added benefit. Chlorzoxazone inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A) , mediators, of type I allergic reactions. Chlorzoxazone also may reduce the release of inflammatory leukotrienes. Chlorzoxazone may act by inhibiting calcium influx.

Pharmacokinetics

After oral administration aceclofenac is rapidly and completely absorbed. Peak plasma concentration Cmax of 6.8 to 8.9 mg/L is reached in about 1.25 to 2 hrs. Pharmacokuinetics properties do not change during multiple administrations. Cmax absorption and volume of distribution are not affected by age and therefore dose reduction is generally not necessary in elderly patients.The presence of food reduces the rate, but not the extrent of absorption of aceclofenac.

Interactions

Aceclofenac may increase the plasm concentrations of lithium and digoxin. Concomittant use of aceclofenac and diuretics may inhibit the activity of diuretics. The activity of anticoagulants may be enhanced when used concomittantl with aceclofenac . Additive CNS depression may occur when chlorzoxazone is administred concomittantly with other CNS depressants. including alcohol. Absorption of paracetamol may be reduced by pethidine and propantheline